• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

Wockhardt receives US FDA approval for Olopatadine HCI

financialexpressJuly 04, 2017

Tag: WOCKHARDT , FDA

Wockhardt has received final approval from US FDA for its ANDA for 0.1 per cent ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1 per cent ophthalmic solution is a generic version of Patanol, marketed at a US by Alcon, a subsidiary of Novartis

The product will be manufactured at US FDA approved contract manufacturing organisation based in Montreal, Canada.

Previous:Convergence of Blockchain with Emerging Technologies Set to Disrupt the Healthcare Industry by 2025

Next:Domino Printech India to launch Ax-Series

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Wockhardt receives US FDA approval for Olopatadine HCI | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Mesnaum (FDA)

Mesnaum (FDA)
Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)
Lincomycin HCL (FDA)

Lincomycin HCL (FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Bumetanide (FDA)

Bumetanide (FDA)
HFHA(m-6FDAP)

HFHA(m-6FDAP)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service